Physician Views – Defining a suitable NASH therapy
Excitement around the opportunity for therapies that are designed to treat nonalcoholic steatohepatitis (NASH) continues to grow and with little surprise.
Due to the lack of approved or satisfactory treatments, as well as the increasing prevalence of this disease, there remains high unmet in the treatment of NASH and therefore, high commercial potential for a successful NASH treatment. Currently there are several promising agents in Phase II trials that are being developed to address fat accumulation and inflammation in the liver, as well as potentially reverse the fibrosis caused by NASH.
A forthcoming NASH report by FirstWord's Therapy Trends brand –utilises interviews with 12 key opinion leaders (KOLs) to assess the current and future treatment landscape in NASH.
Reasons to Purchase
One concluding piece of analysis from this forthcoming report is a summary of the product characteristics for an ideal NASH therapy, as based on KOL feedback. This Physician Views poll uses that summary as inspiration and asks US and EU5-based gastroenterologists (taking into account the current treatment paradigm) to provide their feedback on the following product characteristics…
A treatment for NASH should be orally administered once daily
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook